Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
Portfolio Pulse from
Aethlon Medical reported its fiscal second quarter results and announced the enrollment of the first two patients in its Hemopurifier® study for solid tumors. Two Australian sites are now open for patient enrollment. A conference call is scheduled for today.
November 13, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aethlon Medical announced its fiscal Q2 results and significant progress in its Hemopurifier® study, enrolling the first patients and opening two Australian sites for the trial.
The enrollment of the first patients in the Hemopurifier® study and the opening of new sites are positive developments, indicating progress in Aethlon's research efforts. This could boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100